evaluate novo nordisk on glp-1 agonists Bolsters Portfolio With OZEMPIC's New Approval GLP-1 Receptor Agonist Market Size,

doi: 10.1097/MD.0000000000026086 45 ZhangFChenZWuDTianLChenQYeYet al

A systematic literature review and network metaanalysis comparing onceweekly semaglutide with other GLP1 receptor agonists in patients with type 2 diabetes previously receiving 12 oral antidiabetic drugs

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Data submitting to ICSRs with GLP-1 RAs as suspected drugs were extracted from the FAERS database spanning the period between January 2005 and September 2023

The administration of liraglutide was associated with a significantly decreased risk of incident bone fractures (MH-OR: 0.38, 95% CI: 0.17-0.87), while exenatide administration was linked with an increased risk (MH-OR: 2.09, 95% CI: 1.03-4.21)

In particular, GLP-1 analogues have shown direct effects on the plasticity of the pancreatic islet in both normal glucose tolerance and throughout the whole spectrum of alterations leading to overt diabetes [7]